Department of Endocrinology, Monash Health, Victoria, Australia.
Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Victoria, Australia.
Clin Endocrinol (Oxf). 2024 Jan;100(1):3-18. doi: 10.1111/cen.14659. Epub 2021 Dec 21.
To formulate clinical consensus recommendations on the presentation, assessment, and management of primary hyperparathyroidism (PHPT) in adults.
Representatives from relevant Australian and New Zealand Societies used a systematic approach for adaptation of guidelines (ADAPTE) to derive an evidence-informed position statement addressing nine key questions.
PHPT is a biochemical diagnosis. Serum calcium should be measured in patients with suggestive symptoms, reduced bone mineral density or minimal trauma fractures, and in those with renal stones. Other indications are detailed in the manuscript. In patients with hypercalcaemia, intact parathyroid hormone, 25-hydroxy vitamin D, phosphate, and renal function should be measured. In established PHPT, assessment of bone mineral density, vertebral fractures, urinary tract calculi/nephrocalcinosis and quantification of urinary calcium excretion is warranted. Parathyroidectomy is the only definitive treatment and is warranted for all symptomatic patients and should be considered for asymptomatic patients without contraindications to surgery and with >10 years life expectancy. In patients who do not undergo surgery, we recommend annual evaluation for disease progression. Where the diagnosis is not clear or the risk-benefit ratio is not obvious, multidisciplinary discussion and formulation of a consensus management plan is appropriate. Genetic testing for familial hyperparathyroidism is recommended in selected patients.
These clinical consensus recommendations were developed to provide clinicians with contemporary guidance on the assessment and management of PHPT in adults. It is anticipated that improved health outcomes for individuals and the population will be achieved at a decreased cost to the community.
制定成人原发性甲状旁腺功能亢进症(PHPT)表现、评估和管理的临床共识建议。
澳大利亚和新西兰相关学会的代表采用系统方法(ADAPTE)改编指南,以得出一份针对九个关键问题的循证立场声明。
PHPT 是一种生化诊断。有提示症状、骨密度降低或轻微创伤性骨折以及有肾结石的患者应检测血清钙。其他适应症在本文档中有详细说明。血钙升高的患者应检测完整甲状旁腺激素、25-羟维生素 D、磷酸盐和肾功能。对于已确诊的 PHPT,应评估骨密度、椎体骨折、尿路结石/肾钙质沉着症和尿钙排泄量。甲状旁腺切除术是唯一的确定性治疗方法,所有有症状的患者都需要手术,对于无手术禁忌且预期寿命超过 10 年的无症状患者也应考虑手术。对于不接受手术的患者,我们建议每年评估疾病进展情况。对于诊断不明确或风险效益比不明显的患者,应进行多学科讨论并制定共识管理计划。建议对家族性甲状旁腺功能亢进症患者进行基因检测。
这些临床共识建议旨在为临床医生提供有关成人 PHPT 评估和管理的当代指导。预计将以降低社区成本为代价,改善个人和人群的健康结果。